[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026",
    "summary": "Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=598df7049377e0fe4c94065e6eabf54853a35b89d0257c8ec8a6dd09bab40b87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770395977,
      "headline": "Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026",
      "id": 138379417,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2252188756/image_2252188756.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=598df7049377e0fe4c94065e6eabf54853a35b89d0257c8ec8a6dd09bab40b87"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Subdued 2026 Outlook: What it Means After Q4 Results?",
    "summary": "MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.",
    "url": "https://finnhub.io/api/news?id=5b136ac6391a3dec6d665fb65169bf4e7dc20719168bc6893babb76d3e3172b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770393840,
      "headline": "Merck's Subdued 2026 Outlook: What it Means After Q4 Results?",
      "id": 138376827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.",
      "url": "https://finnhub.io/api/news?id=5b136ac6391a3dec6d665fb65169bf4e7dc20719168bc6893babb76d3e3172b3"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs",
    "summary": "Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...",
    "url": "https://finnhub.io/api/news?id=352251e5b12f115eecc293d0f735cbf9985cea0a27856617ff0c594860c3e723",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770393002,
      "headline": "Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs",
      "id": 138378217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...",
      "url": "https://finnhub.io/api/news?id=352251e5b12f115eecc293d0f735cbf9985cea0a27856617ff0c594860c3e723"
    }
  },
  {
    "ts": null,
    "headline": "Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study",
    "summary": "Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.",
    "url": "https://finnhub.io/api/news?id=7d7045818d5d4740b6254fd3521b5728e67169ea935108cf2e8d587c6aa2da33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770392760,
      "headline": "Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study",
      "id": 138376828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.",
      "url": "https://finnhub.io/api/news?id=7d7045818d5d4740b6254fd3521b5728e67169ea935108cf2e8d587c6aa2da33"
    }
  },
  {
    "ts": null,
    "headline": "Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic",
    "summary": "USMV and other low-volatility ETFs gain appeal as an AI-driven tech rout wipes $1T, spikes VIX, and fuels rotation into staples and value sectors.",
    "url": "https://finnhub.io/api/news?id=004d2a54ba933d557c0e25a45c8ed721ecbeed95b385dd6f0bfb572e198fa10b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770388080,
      "headline": "Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic",
      "id": 138376826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "USMV and other low-volatility ETFs gain appeal as an AI-driven tech rout wipes $1T, spikes VIX, and fuels rotation into staples and value sectors.",
      "url": "https://finnhub.io/api/news?id=004d2a54ba933d557c0e25a45c8ed721ecbeed95b385dd6f0bfb572e198fa10b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=8739bc9d8102a86888d71284fb797d3cc2b6bb6c14f1c2bfea9d67261ba7641e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770386405,
      "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
      "id": 138375433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=8739bc9d8102a86888d71284fb797d3cc2b6bb6c14f1c2bfea9d67261ba7641e"
    }
  }
]